InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
66,817.16
(
-0.53%
)
Post# of 252642
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120081
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 177608

Saturday, 09/27/2014 3:50:05 PM

Saturday, September 27, 2014 3:50:05 PM

Post# of 252642
AZN reports early data for anti-PD-1/CTLA4 combination of MEDI4736 + Tremelimumab:

http://in.reuters.com/article/2014/09/27/us-health-cancer-astrazeneca-idINKCN0HM0AD20140927

Tremelimumab, the anti-CTLA4 drug in the combination, was licensed from PFE in 2011(#msg-67624944).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up